RecruitingNCT06862700

Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients

Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study

Sponsor

Xiaotong Hou

Enrollment

534 participants

Start Date

Feb 26, 2025

Study Type

OBSERVATIONAL

Conditions

Heart Failure Cardiogenic Shock Extracorporeal Membrane Oxygenation Vasopressors Hemodynamic Management Critical Care

Summary

The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
First-time ECMO initiation.
Venoarterial ECMO (VA-ECMO) as the initial mode.

Exclusion Criteria4

Age \<18 years.
Severe pulmonary hypertension.
Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).
Severe missing data.

Interventions

OTHERVasopressor Exposure Levels

This is an observational study with no active intervention. The study evaluates the association between natural variations in vasopressor exposure levels (measured by Vasoactive-Inotropic Score, VIS) and clinical outcomes in patients receiving VA-ECMO for cardiogenic shock.